AzTrials
AzTrials

Pulmonary Disease, Chronic ObstructiveNCT01036763

Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example

An observational study of Pulmonary Disease, Chronic Obstructive, run by Boehringer Ingelheim at 352 sites in Germany.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Documentation of successful therapy with tiotropium (Spiriva Respimat; Spiriva (tiotropium 18 mcg capsules)) in COPD patients requiring long-acting bronchodilators: description of the most important outcome parameters according to the physicians assessment to determine the success of therapy. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pulmonary Disease, Chronic Obstructive
How many people
Not given
Where
352 sitesGermany
Study dates
Jan 2010to Aug 2010
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients

Inclusion criteria COPD patients requiring long-acting bronchodilators according to approved Summary of Product Characteristics (SPC) and guidelines

Exclusion criteria Patients cannot be recruited if any of the general or specific contraindications listed in the Patient information leaflet or the Summary of Product Characteristics applies.

Trial locations and contacts

352 sites in 1 country.

300 sites in 1 country

Germany300 sites

  • Boehringer Ingelheim Investigational Site 1

    Ahrensburg

  • Boehringer Ingelheim Investigational Site 2

    Amberg

  • Boehringer Ingelheim Investigational Site 3

    Arnstadt

  • Boehringer Ingelheim Investigational Site 4

    Auerbach

  • Boehringer Ingelheim Investigational Site 10

    Augsburg

  • Boehringer Ingelheim Investigational Site 5

    Augsburg

  • Boehringer Ingelheim Investigational Site 6

    Augsburg

  • Boehringer Ingelheim Investigational Site 7

    Augsburg

  • Boehringer Ingelheim Investigational Site 8

    Augsburg

  • Boehringer Ingelheim Investigational Site 9

    Augsburg

  • Boehringer Ingelheim Investigational Site 11

    Backnang

  • Boehringer Ingelheim Investigational Site 12

    Bad Doberan

  • Boehringer Ingelheim Investigational Site 13

    Bad Kissingen

  • Boehringer Ingelheim Investigational Site 15

    Bad Kötzting

  • Boehringer Ingelheim Investigational Site 16

    Bad Kötzting

  • Boehringer Ingelheim Investigational Site 14

    Bad Krozingen

  • Boehringer Ingelheim Investigational Site 17

    Bad Lippspringe

  • Boehringer Ingelheim Investigational Site 18

    Bad Neuenahr-Ahrweiler

  • Boehringer Ingelheim Investigational Site 19

    Bad Neustadt an der Saale

  • Boehringer Ingelheim Investigational Site 20

    Bad Reichenhall

  • Boehringer Ingelheim Investigational Site 21

    Bad Reichenhall

  • Boehringer Ingelheim Investigational Site 22

    Bad Sachsa

  • Boehringer Ingelheim Investigational Site 23

    Bad Wörishofen

  • Boehringer Ingelheim Investigational Site 24

    Baden-Baden

  • Boehringer Ingelheim Investigational Site 25

    Ballenstedt

  • Boehringer Ingelheim Investigational Site 26

    Bamberg

  • Boehringer Ingelheim Investigational Site 27

    Bautzen

  • Boehringer Ingelheim Investigational Site 28

    Beelitz

  • Boehringer Ingelheim Investigational Site 29

    Bensheim

  • Boehringer Ingelheim Investigational Site 30

    Bergisch Gladbach

  • Boehringer Ingelheim Investigational Site 31

    Berlin

  • Boehringer Ingelheim Investigational Site 32

    Berlin

  • Boehringer Ingelheim Investigational Site 33

    Berlin

  • Boehringer Ingelheim Investigational Site 34

    Berlin

  • Boehringer Ingelheim Investigational Site 35

    Berlin

  • Boehringer Ingelheim Investigational Site 36

    Berlin

  • Boehringer Ingelheim Investigational Site 37

    Berlin

  • Boehringer Ingelheim Investigational Site 38

    Berlin

  • Boehringer Ingelheim Investigational Site 39

    Berlin

  • Boehringer Ingelheim Investigational Site 40

    Berlin

  • Boehringer Ingelheim Investigational Site 41

    Berlin

  • Boehringer Ingelheim Investigational Site 42

    Berlin

  • Boehringer Ingelheim Investigational Site 43

    Berlin

  • Boehringer Ingelheim Investigational Site 44

    Berlin

  • Boehringer Ingelheim Investigational Site 45

    Berlin

  • Boehringer Ingelheim Investigational Site 46

    Berlin

  • Boehringer Ingelheim Investigational Site 47

    Berlin

  • Boehringer Ingelheim Investigational Site 48

    Berlin

  • Boehringer Ingelheim Investigational Site 49

    Berlin

  • Boehringer Ingelheim Investigational Site 50

    Berlin

  • Boehringer Ingelheim Investigational Site 51

    Berlin

  • Boehringer Ingelheim Investigational Site 52

    Berlin

  • Boehringer Ingelheim Investigational Site 53

    Bernau

  • Boehringer Ingelheim Investigational Site 54

    Bitterfeld-Wolfen

  • Boehringer Ingelheim Investigational Site 55

    Bochum

  • Boehringer Ingelheim Investigational Site 56

    Bochum

  • Boehringer Ingelheim Investigational Site 57

    Bonn

  • Boehringer Ingelheim Investigational Site 58

    Bonn

  • Boehringer Ingelheim Investigational Site 59

    Bonn

  • Boehringer Ingelheim Investigational Site 60

    Bonn

  • Boehringer Ingelheim Investigational Site 61

    Bottrop

  • Boehringer Ingelheim Investigational Site 62

    Braunschweig

  • Boehringer Ingelheim Investigational Site 63

    Braunschweig

  • Boehringer Ingelheim Investigational Site 64

    Bremen

  • Boehringer Ingelheim Investigational Site 65

    Bremen

  • Boehringer Ingelheim Investigational Site 66

    Bremen

  • Boehringer Ingelheim Investigational Site 67

    Bremen

  • Boehringer Ingelheim Investigational Site 68

    Bremerhaven

  • Boehringer Ingelheim Investigational Site 69

    Bremerhaven

  • Boehringer Ingelheim Investigational Site 70

    Bruchsal

  • Boehringer Ingelheim Investigational Site 71

    Buchholz

  • Boehringer Ingelheim Investigational Site 72

    Castrop-Rauxel

  • Boehringer Ingelheim Investigational Site 73

    Celle

  • Boehringer Ingelheim Investigational Site 74

    Celle

  • Boehringer Ingelheim Investigational Site 75

    Chemnitz

  • Boehringer Ingelheim Investigational Site 76

    Coburg

  • Boehringer Ingelheim Investigational Site 77

    Coburg

  • Boehringer Ingelheim Investigational Site 200

    Cologne

  • Boehringer Ingelheim Investigational Site 201

    Cologne

  • Boehringer Ingelheim Investigational Site 202

    Cologne

  • Boehringer Ingelheim Investigational Site 78

    Cottbus

  • Boehringer Ingelheim Investigational Site 79

    Cottbus

  • Boehringer Ingelheim Investigational Site 80

    Dachau

  • Boehringer Ingelheim Investigational Site 81

    Darmstadt

  • Boehringer Ingelheim Investigational Site 82

    Deggendorf

  • Boehringer Ingelheim Investigational Site 83

    Delitzsch

  • Boehringer Ingelheim Investigational Site 84

    Dessau

  • Boehringer Ingelheim Investigational Site 85

    Dillingen

  • Boehringer Ingelheim Investigational Site 86

    Dillingen

  • Boehringer Ingelheim Investigational Site 87

    Donaueschingen

  • Boehringer Ingelheim Investigational Site 88

    Dorsten

  • Boehringer Ingelheim Investigational Site 89

    Dortmund

  • Boehringer Ingelheim Investigational Site 90

    Dresden

  • Boehringer Ingelheim Investigational Site 91

    Dresden

  • Boehringer Ingelheim Investigational Site 92

    Dresden

  • Boehringer Ingelheim Investigational Site 93

    Dresden

  • Boehringer Ingelheim Investigational Site 94

    Dresden

  • Boehringer Ingelheim Investigational Site 95

    Dresden

  • Boehringer Ingelheim Investigational Site 96

    Dresden

  • Boehringer Ingelheim Investigational Site 97

    Düren

  • Boehringer Ingelheim Investigational Site 98

    Düren

  • Boehringer Ingelheim Investigational Site 100

    Düsseldorf

  • Boehringer Ingelheim Investigational Site 101

    Düsseldorf

  • Boehringer Ingelheim Investigational Site 102

    Düsseldorf

  • Boehringer Ingelheim Investigational Site 99

    Düsseldorf

  • Boehringer Ingelheim Investigational Site 103

    Eichstätt

  • Boehringer Ingelheim Investigational Site 104

    Emden

  • Boehringer Ingelheim Investigational Site 105

    Erbach im Odenwald

  • Boehringer Ingelheim Investigational Site 106

    Erfurt

  • Boehringer Ingelheim Investigational Site 107

    Erfurt

  • Boehringer Ingelheim Investigational Site 108

    Erfurt

  • Boehringer Ingelheim Investigational Site 109

    Erlangen

  • Boehringer Ingelheim Investigational Site 110

    Eschwege

  • Boehringer Ingelheim Investigational Site 111

    Esslingen am Neckar

  • Boehringer Ingelheim Investigational Site 112

    Esslingen am Neckar

  • Boehringer Ingelheim Investigational Site 113

    Euskirchen

  • Boehringer Ingelheim Investigational Site 114

    Fellbach

  • Boehringer Ingelheim Investigational Site 115

    Flensburg

  • Boehringer Ingelheim Investigational Site 123

    Föhren

  • Boehringer Ingelheim Investigational Site 116

    Forchheim

  • Boehringer Ingelheim Investigational Site 117

    Frankenthal

  • Boehringer Ingelheim Investigational Site 118

    Frankfurt

  • Boehringer Ingelheim Investigational Site 119

    Frankfurt

  • Boehringer Ingelheim Investigational Site 120

    Frankfurt

  • Boehringer Ingelheim Investigational Site 121

    Frankfurt

  • Boehringer Ingelheim Investigational Site 122

    Freising

  • Boehringer Ingelheim Investigational Site 124

    Fürstenfeldbruck

  • Boehringer Ingelheim Investigational Site 125

    Fürth

  • Boehringer Ingelheim Investigational Site 126

    Fürth

  • Boehringer Ingelheim Investigational Site 127

    Ganderkesee

  • Boehringer Ingelheim Investigational Site 128

    Gauting

  • Boehringer Ingelheim Investigational Site 129

    Geilenkirchen

  • Boehringer Ingelheim Investigational Site 130

    Gelsenkirchen

  • Boehringer Ingelheim Investigational Site 131

    Gelsenkirchen

  • Boehringer Ingelheim Investigational Site 132

    Gera

  • Boehringer Ingelheim Investigational Site 133

    Germering

  • Boehringer Ingelheim Investigational Site 134

    Giessen

  • Boehringer Ingelheim Investigational Site 135

    Giessen

  • Boehringer Ingelheim Investigational Site 140

    Göppingen

  • Boehringer Ingelheim Investigational Site 141

    Göttingen

  • Boehringer Ingelheim Investigational Site 142

    Göttingen

  • Boehringer Ingelheim Investigational Site 143

    Göttingen

  • Boehringer Ingelheim Investigational Site 136

    Greiz

  • Boehringer Ingelheim Investigational Site 137

    Grevesmühlen

  • Boehringer Ingelheim Investigational Site 138

    Großenhain

  • Boehringer Ingelheim Investigational Site 139

    Gummersbach

  • Boehringer Ingelheim Investigational Site 144

    Günzburg

  • Boehringer Ingelheim Investigational Site 145

    Gütersloh

  • Boehringer Ingelheim Investigational Site 146

    Gütersloh

  • Boehringer Ingelheim Investigational Site 147

    Gütersloh

  • Boehringer Ingelheim Investigational Site 148

    Hagen

  • Boehringer Ingelheim Investigational Site 149

    Halberstadt

  • Boehringer Ingelheim Investigational Site 150

    Halle

  • Boehringer Ingelheim Investigational Site 151

    Halle

  • Boehringer Ingelheim Investigational Site 152

    Hamburg

  • Boehringer Ingelheim Investigational Site 153

    Hamburg

  • Boehringer Ingelheim Investigational Site 154

    Hamburg

  • Boehringer Ingelheim Investigational Site 155

    Hamburg

  • Boehringer Ingelheim Investigational Site 156

    Hamburg

  • Boehringer Ingelheim Investigational Site 157

    Hamburg

  • Boehringer Ingelheim Investigational Site 158

    Hamburg

  • Boehringer Ingelheim Investigational Site 159

    Hamburg

  • Boehringer Ingelheim Investigational Site 160

    Hamburg

  • Boehringer Ingelheim Investigational Site 161

    Hamburg

  • Boehringer Ingelheim Investigational Site 162

    Hamburg

  • Boehringer Ingelheim Investigational Site 163

    Hamm

  • Boehringer Ingelheim Investigational Site 164

    Hanover

  • Boehringer Ingelheim Investigational Site 165

    Hanover

  • Boehringer Ingelheim Investigational Site 166

    Hanover

  • Boehringer Ingelheim Investigational Site 167

    Hanover

  • Boehringer Ingelheim Investigational Site 168

    Hartha

  • Boehringer Ingelheim Investigational Site 169

    Heidelberg

  • Boehringer Ingelheim Investigational Site 170

    Heidelberg

  • Boehringer Ingelheim Investigational Site 171

    Heidelberg

  • Boehringer Ingelheim Investigational Site 172

    Heidelberg

  • Boehringer Ingelheim Investigational Site 173

    Heilbronn

  • Boehringer Ingelheim Investigational Site 174

    Heilbronn

  • Boehringer Ingelheim Investigational Site 175

    Hemmingen

  • Boehringer Ingelheim Investigational Site 176

    Hemmingen

  • Boehringer Ingelheim Investigational Site 177

    Herne

  • Boehringer Ingelheim Investigational Site 178

    Hettstedt

  • Boehringer Ingelheim Investigational Site 179

    Hilden

  • Boehringer Ingelheim Investigational Site 180

    Husum

  • Boehringer Ingelheim Investigational Site 181

    Itzehoe

  • Boehringer Ingelheim Investigational Site 182

    Itzehoe

  • Boehringer Ingelheim Investigational Site 183

    Kaiserslautern

  • Boehringer Ingelheim Investigational Site 184

    Kaiserslautern

  • Boehringer Ingelheim Investigational Site 185

    Kamen

  • Boehringer Ingelheim Investigational Site 186

    Karlsruhe

  • Boehringer Ingelheim Investigational Site 187

    Karlsruhe

  • Boehringer Ingelheim Investigational Site 188

    Kempten

  • Boehringer Ingelheim Investigational Site 189

    Kiel

  • Boehringer Ingelheim Investigational Site 190

    Kiel

  • Boehringer Ingelheim Investigational Site 191

    Kiel

  • Boehringer Ingelheim Investigational Site 192

    Kirchheim

  • Boehringer Ingelheim Investigational Site 193

    Koblenz

  • Boehringer Ingelheim Investigational Site 194

    Koblenz

  • Boehringer Ingelheim Investigational Site 195

    Koblenz

  • Boehringer Ingelheim Investigational Site 196

    Koblenz

  • Boehringer Ingelheim Investigational Site 203

    Königs Wusterhausen

  • Boehringer Ingelheim Investigational Site 197

    Konstanz

  • Boehringer Ingelheim Investigational Site 204

    Köthen

  • Boehringer Ingelheim Investigational Site 198

    Krefeld

  • Boehringer Ingelheim Investigational Site 199

    Krefeld

  • Boehringer Ingelheim Investigational Site 205

    Landshut

  • Boehringer Ingelheim Investigational Site 206

    Langen

  • Boehringer Ingelheim Investigational Site 207

    Langenfeld

  • Boehringer Ingelheim Investigational Site 208

    Langenfeld

  • Boehringer Ingelheim Investigational Site 209

    Leipzig

  • Boehringer Ingelheim Investigational Site 210

    Leipzig

  • Boehringer Ingelheim Investigational Site 211

    Leipzig

  • Boehringer Ingelheim Investigational Site 212

    Leonberg

  • Boehringer Ingelheim Investigational Site 213

    Leverkusen

  • Boehringer Ingelheim Investigational Site 214

    Leverkusen

  • Boehringer Ingelheim Investigational Site 215

    Lichtenfels

  • Boehringer Ingelheim Investigational Site 216

    Limburg

  • Boehringer Ingelheim Investigational Site 217

    Lippstadt

  • Boehringer Ingelheim Investigational Site 221

    Loerrach

  • Boehringer Ingelheim Investigational Site 218

    Ludwigshafen

  • Boehringer Ingelheim Investigational Site 219

    Ludwigshafen

  • Boehringer Ingelheim Investigational Site 222

    Lüneburg

  • Boehringer Ingelheim Investigational Site 223

    Lüneburg

  • Boehringer Ingelheim Investigational Site 224

    Lützen

  • Boehringer Ingelheim Investigational Site 225

    Magdeburg

  • Boehringer Ingelheim Investigational Site 226

    Magdeburg

  • Boehringer Ingelheim Investigational Site 227

    Mainz

  • Boehringer Ingelheim Investigational Site 228

    Mainz

  • Boehringer Ingelheim Investigational Site 229

    Mannheim

  • Boehringer Ingelheim Investigational Site 230

    Mannheim

  • Boehringer Ingelheim Investigational Site 231

    Marburg

  • Boehringer Ingelheim Investigational Site 232

    Markkleeberg

  • Boehringer Ingelheim Investigational Site 233

    Marktredwitz

  • Boehringer Ingelheim Investigational Site 234

    Menden

  • Boehringer Ingelheim Investigational Site 235

    Minden

  • Boehringer Ingelheim Investigational Site 236

    Minden

  • Boehringer Ingelheim Investigational Site 237

    Mönchengladbach

  • Boehringer Ingelheim Investigational Site 238

    Mönchengladbach

  • Boehringer Ingelheim Investigational Site 239

    Mönchengladbach

  • Boehringer Ingelheim Investigational Site 240

    Mühlhausen

  • Boehringer Ingelheim Investigational Site 241

    München

  • Boehringer Ingelheim Investigational Site 242

    München

  • Boehringer Ingelheim Investigational Site 243

    München

  • Boehringer Ingelheim Investigational Site 244

    München

  • Boehringer Ingelheim Investigational Site 245

    München

  • Boehringer Ingelheim Investigational Site 246

    München

  • Boehringer Ingelheim Investigational Site 247

    München

  • Boehringer Ingelheim Investigational Site 248

    München

  • Boehringer Ingelheim Investigational Site 249

    Münster

  • Boehringer Ingelheim Investigational Site 250

    Münster

  • Boehringer Ingelheim Investigational Site 251

    Münster

  • Boehringer Ingelheim Investigational Site 252

    Neu-Ulm

  • Boehringer Ingelheim Investigational Site 253

    Neumarkt

  • Boehringer Ingelheim Investigational Site 254

    Neuwied

  • Boehringer Ingelheim Investigational Site 255

    Niesky

  • Boehringer Ingelheim Investigational Site 256

    Norderstedt

  • Boehringer Ingelheim Investigational Site 257

    Norderstedt

  • Boehringer Ingelheim Investigational Site 258

    Nordhausen

  • Boehringer Ingelheim Investigational Site 259

    Nuremberg

  • Boehringer Ingelheim Investigational Site 260

    Nuremberg

  • Boehringer Ingelheim Investigational Site 261

    Nuremberg

  • Boehringer Ingelheim Investigational Site 262

    Nuremberg

  • Boehringer Ingelheim Investigational Site 263

    Oberursel

  • Boehringer Ingelheim Investigational Site 264

    Offenburg

  • Boehringer Ingelheim Investigational Site 265

    Olpe

  • Boehringer Ingelheim Investigational Site 266

    Oranienburg

  • Boehringer Ingelheim Investigational Site 267

    Oschatz

  • Boehringer Ingelheim Investigational Site 268

    Oschersleben

  • Boehringer Ingelheim Investigational Site 269

    Osnabrück

  • Boehringer Ingelheim Investigational Site 270

    Parsberg

  • Boehringer Ingelheim Investigational Site 271

    Peine

  • Boehringer Ingelheim Investigational Site 272

    Pforzheim

  • Boehringer Ingelheim Investigational Site 273

    Plauen

  • Boehringer Ingelheim Investigational Site 274

    Plauen

  • Boehringer Ingelheim Investigational Site 275

    Plauen

  • Boehringer Ingelheim Investigational Site 276

    Potsdam

  • Boehringer Ingelheim Investigational Site 277

    Pulheim

  • Boehringer Ingelheim Investigational Site 278

    Rathenow

  • Boehringer Ingelheim Investigational Site 279

    Ratingen

  • Boehringer Ingelheim Investigational Site 280

    Raubach

  • Boehringer Ingelheim Investigational Site 281

    Regensburg

  • Boehringer Ingelheim Investigational Site 282

    Remscheid

  • Boehringer Ingelheim Investigational Site 283

    Remscheid

  • Boehringer Ingelheim Investigational Site 284

    Rostock

  • Boehringer Ingelheim Investigational Site 285

    Rostock

  • Boehringer Ingelheim Investigational Site 286

    Roth

  • Boehringer Ingelheim Investigational Site 287

    Rottach-Egern

  • Boehringer Ingelheim Investigational Site 288

    Rüsselsheim am Main

  • Boehringer Ingelheim Investigational Site 289

    Rüsselsheim am Main

  • Boehringer Ingelheim Investigational Site 290

    Saalfeld

  • Boehringer Ingelheim Investigational Site 291

    Saarbrücken

  • Boehringer Ingelheim Investigational Site 292

    Saarbrücken

  • Boehringer Ingelheim Investigational Site 293

    Saarbrücken

  • Boehringer Ingelheim Investigational Site 294

    Saarbrücken

  • Boehringer Ingelheim Investigational Site 295

    Saarbrücken

  • Boehringer Ingelheim Investigational Site 296

    Saarlouis

  • Boehringer Ingelheim Investigational Site 297

    Saarlouis

  • Boehringer Ingelheim Investigational Site 314

    Saint Ingbert

  • Boehringer Ingelheim Investigational Site 298

    Salzgitter

  • Boehringer Ingelheim Investigational Site 299

    Schmallenberg

  • Boehringer Ingelheim Investigational Site 300

    Schmölln

Other trials in Germany

About this study

Official title: Assessment of COPD Therapy From the Physicians Perspective Using Tiotropium as an Example

Documentation of successful therapy with tiotropium (Spiriva Respimat; Spiriva (tiotropium 18 mcg capsules)) in COPD patients requiring long-acting bronchodilators: description of the most important outcome parameters according to the physicians assessment to determine the success of therapy. Such data are not yet available.

Also collection of physicians assessments and patients assessments of efficacy and tolerability of Spiriva Respimat, Spiriva (tiotropium 18 mcg capsules).

Read the detailed description

Study Design:

observational

Medical subject headings
Pulmonary Disease, Chronic Obstructive

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Success of Treatment With Tiotropium According to Physician's Assessment

    Evaluation of important outcome parameters (pulmonary function, dyspnoe, health-related quality of life, exercise capacity, prevention of exacerbations) which were used for the physician´s decision to assess the treatment as successful

    Measured: 6 - 12 weeks

  2. Assessment of Efficacy According to Physician

    Physician's assessment of efficacy within categories (positive/ negative), concurrent proportion of positive efficacy assessments by both physician and patient was determined

    Measured: 6 - 12 weeks

  3. Assessment of Tolerability According to Physician

    Physician's assessment of tolerability (positve/ negative), concurrent proportion of positive efficacy assessments by both physician and patient was determined

    Measured: 6 - 12 weeks

  4. Assessment of Efficacy According to Patient

    patient-reported assessment within categories (Very good, good, satisfactory, less satisfactory, unsatisfactory, missing)

    Measured: 6 - 12 weeks

  5. Assessment of Tolerability According to Patient

    Patient-reported assessment within categories (Very good, good, satisfactory, less satisfactory, unsatisfactory, missing)

    Measured: 6 - 12 weeks

Secondary outcomes (2)

  1. Physician's Global Evaluation at Visit 1

    Physician's global evaluation (PGE) of the patients' general condition at Visit 1 evaluated on an 8-point scale with the scores "Poor (1, 2)", "Satisfactory (3, 4)", "Good (5, 6)" and "Excellent (7, 8)" prior to treatment with Spiriva.

    Measured: 0 weeks

  2. Physician's Global Evaluation at Visit 2

    Physician's global evaluation (PGE) of the patients' general condition at Visit 2 evaluated on an 8-point scale after approximately 6-12 weeks of treatment with Spiriva.

    Measured: after 6 - 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Dec 2009 (estimated)
  2. Study startJan 2010
  3. Primary completionAug 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Time perspective
Prospective
IDs, dates and publications
ClinicalTrials.gov ID
NCT01036763
Sponsor's protocol ID
205.455
Status last verified
Feb 2014
First submitted
18 Dec 2009
Last updated
27 Mar 2014

Publications

  • Rau-Berger H, Kroker A, Mitfessel H, Schmidt H, Glaab T Assessment of COPD-therapy with tiotropium by the treating pneumologist. 53rd Cong of the German Respiratory Society, Nuremberg, 29 Mar - 1 Apr 2012 (Poster), (2012)

  • Glaab T, Kroker A, Mitfessel H, Schmdit H, Rau-Berger H Evaluation of COPD treatment success by office-based pneumologists using the example of tiotropium. 21st Ann Cong of the European Respiratory Society (ERS), Amsterdam, 24 - 28 Sep 2011 (Poster), (2011)

Questions about this trial

What is this clinical trial studying?

An observational study of Pulmonary Disease, Chronic Obstructive, run by Boehringer Ingelheim at 352 sites in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Mar 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 352 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 22 Mar 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Success of Treatment With Tiotropium According to Physician's Assessment (time frame: 6 - 12 weeks). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01036763, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2014; AzTrials last refreshed its copy on 7 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in